FindTrial
Sign In

CCS1477

DRUG2 trials

Sponsors

CellCentric Ltd.

Conditions

Acute Myeloid LeukemiaAdvanced Solid TumorsHaematological MalignancyHigher-risk Myelodysplastic SyndromeMetastatic Breast CancerMetastatic Castration-Resistant Prostate CancerMultiple MyelomaNon Hodgkin Lymphoma

Phase 1

Study to Evaluate CCS1477 in Advanced Tumours
CompletedNCT03568656
CellCentric Ltd.Advanced Solid Tumors, Metastatic Breast Cancer, Metastatic Castration-Resistant Prostate Cancer +1
Start: 2018-07-23End: 2025-07-06Updated: 2025-08-08
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
RecruitingNCT04068597
CellCentric Ltd.Acute Myeloid Leukemia, Haematological Malignancy, Higher-risk Myelodysplastic Syndrome +3
Start: 2019-08-09End: 2027-03-31Target: 250Updated: 2026-06-24

Related Papers

Targeted degradation of CBP/p300 by CBPD-409 exhibits robust anti-myeloma activity
Leukemia2026-06-16
Randomized phase II dose optimization study of inobrodib (CCS1477), in combination with pomalidomide and dexamethasone in relapsed/refractory multiple myeloma (RRMM)
Blood2025-11-03
Evaluating inobrodib (CCS1477) in combination with teclistamab or elranatamab in patients with Relapsed/Refractory multiple myeloma; Specific cohorts within a Phase I/IIa study evaluating inobrodib in patients with advanced hematological malignancies
Blood2025-11-03
Inhibition of lysine acetyltransferases p300/CBP overcomes BTK inhibitor resistance in a xenograft model of Mantle Cell Lymphoma by suppressing MYC signaling
Blood2025-11-03
IRF4 maintenance in multiple myeloma is conserved in de novo-derived inobrodib resistance, conferring cross resistance to immunomodulatory drugs
Blood2025-11-03
Tolerability and Clinical Activity of Novel First-in-Class Oral Agent, Inobrodib (CCS1477), in Combination with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma
Blood2024-11-052 citations
Investigating the Therapeutic Potential of the Novel CBP/p300 Protein Degrader CBPD409 in Multiple Myeloma
Blood2024-11-051 citations
Tolerability and Clinical Activity of Novel First in Class Oral Agent, Inobrodib (CCS1477), in Combination with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma
Blood2023-11-022 citations
Preclinical and Early Clinical Results Indicate a Role for the Oral p300/CBP Inhibitor Inobrodib (CCS1477) in T-Cell Lymphoma
Blood2023-11-02
P863: AN OPEN-LABEL PHASE I/IIA STUDY TO EVALUATE THE SAFETY AND EFFICACY OF CCS1477 AS MONOTHERAPY AND IN COMBINATION WITH POMALIDOMIDE/DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA
HemaSphere2023-08-012 citations
Abstract CT136: An open-label phase I/IIa study to evaluate the safety and efficacy of CCS1477 as monotherapy and in combination in patients with advanced hematological malignancies
Cancer Research2023-04-141 citations
Potent Pre-Clinical and Early Phase Clinical Activity of EP300/CBP Bromodomain Inhibitor CCS1477 in Multiple Myeloma
Blood2022-11-157 citations
Therapeutic Targeting of EP300/CBP By Bromodomain Inhibition in Acute Myeloid Leukemia
Blood2022-11-156 citations
CCS1477, a Novel p300/CBP Bromodomain Inhibitor, Enhances Efficacy of Azacitidine and Venetoclax in Pre-Clinical Models of Acute Myeloid Leukaemia and Lymphoma
Blood2021-11-0512 citations
An open label phase I/IIa study to evaluate the safety and efficacy of CCS1477 as monotherapy and in combination in patients with advanced solid/metastatic tumors.
Journal of Clinical Oncology2019-05-2013 citations